 |
|
|
|
 |
|
|
| Article 1 to 10 out of 18 concerning Oxford BioMedica plc
|
-
Sanofi-aventis and Oxford Biomedica report encouraging TroVax Phase II results in metastatic renal cancer
(06/04/2008)
Sanofi-aventis and Oxford BioMedica announced encouraging updated results from Phase II trials of TroVax in metastatic (advanced) renal cancer. TroVax is Oxford BioMedica's lead therapeutic cancer vaccine, which is being developed in metastatic ...
-
Oxford BioMedica develops strategic development plan with the commercialisation of TroVax
(03/20/2008)
Oxfordshire Bioscience Network (OBN), organisers of the forth coming Bio Trinity 2008 conference, has confirmed Peter Nolan, SVP Commercial Development at Oxford BioMedica as a lead speaker on this years programme. Mr Nolan will discuss the ...
-
Oxford Biomedica completes patient recruitment for phase III TRIST study of TroVax in renal cancer
(03/11/2008)
Oxford BioMedica announced that it has successfully completed patient enrolment in the Phase III TRIST study of TroVax in renal cancer. TroVax is Oxford BioMedica's novel cancer immunotherapy product, which is being developed in collaboration with ...
-
Oxford Biomedica announces development milestone in its collaboration with MolMed
(01/23/2008)
MolMed gets regulatory approval to start a Phase III trial in Italy of its TK therapy for high risk acute leukaemia
Oxford BioMedica announced that its partner MolMed has received regulatory approval to start a Phase III trial of TK therapy for high risk acute leukaemia. Under a license agreement with Oxford BioMedica, MolMed's TK therapy product employs Oxford ...
-
Oxford Biomedica and Sigma-Aldrich win key ruling in open biosystems patent infringement dispute
(10/29/2007)
Oxford BioMedica and Sigma-Aldrich announced that they received a key order confirming the strength and validity of intellectual property owned by Oxford BioMedica and licensed exclusively in the research field to Sigma-Aldrich. The ruling was part ...
-
Oxford Biomedica and Sanofi-Aventis report new TroVax Phase II trial results in renal cancer
(06/05/2007)
Oxford BioMedica and sanofi-aventis announced new data from two Phase II trials of TroVax® in renal cancer. TroVax® is Oxford BioMedica's lead cancer immunotherapy product, which is being developed in collaboration with sanofi-aventis. The Phase II ...
-
Oxford BioMedica and Sanofi-Aventis enter global licensing agreement to develop and commercialise TroVax for cancer
(03/29/2007)
Oxford BioMedica and sanofi-aventis announced that they have entered into an exclusive global licensing agreement to develop and commercialise TroVax® for the treatment and prevention of cancers. TroVax® is Oxford BioMedica's lead cancer ...
-
oxxon therapeutics to be acquired by Oxford BioMedica
(03/14/2007)
Acquisition consolidates immunotherapy assets
Oxxon Therapeutics Limited announced that it has entered into an agreement to be acquired by Oxford BioMedica. Oxford BioMedica is focused on the development of novel gene-based therapeutics particularly in oncology, including therapeutic vaccines, ...
-
Oxford Biomedica expands its ocular programme through collaboration and investment led by the foundation fighting blindness
(10/05/2006)
Oxford BioMedica and The Foundation Fighting Blindness (FFB) through its translational research arm National Neurovision Research Institute (NNRI) have signed a research and collaboration agreement to develop a portfolio of gene therapy products for ...
-
Oxford Biomedica Receives Notice of Allowance for Key US Patent Covering Parkinson's Disease Product
(06/27/2006)
Oxford BioMedica has received a Notice of Allowance from the US Patent Office for a key patent application, which significantly extends the protection of ProSavin, the Company's lead product candidate for Parkinson's disease. It is expected that the ...
Additional information
Oxford BioMedica plc
Oxford, United Kingdom
Company
|
|
|
|
|
|
Top
